Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages.
暂无分享,去创建一个
[1] J. Mehta,et al. Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-&kgr;B by Losartan in Hypercholesterolemic Rabbits , 2002, Journal of cardiovascular pharmacology.
[2] A. Newby,et al. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. , 2001, Cardiovascular research.
[3] J. Egido,et al. Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] S. Parthasarathy,et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. , 2001, Journal of the American College of Cardiology.
[5] I. Dixon,et al. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. , 2000, Cardiovascular research.
[6] C. Ferrario,et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. , 2000, Circulation.
[7] T. Yu,et al. Effects of angiotensin-converting enzyme and angiotensin II on hypoxia-induced proliferation of cultured intra-pulmonary artery smooth muscle cells. , 2000, Acta pharmacologica Sinica.
[8] H. Drexler,et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. , 2000, Circulation.
[9] A. Takeshita,et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. , 2000, Circulation.
[10] N. Hirose,et al. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. , 1999, Atherosclerosis.
[11] S. Kaul,et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.
[12] U. Nannmark,et al. Matrix metalloproteinases produced by rat IL-2-activated NK cells. , 1998, Journal of immunology.
[13] G. Callis,et al. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Breslow,et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. , 1997, Biochemical and biophysical research communications.
[15] G. Berry,et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. , 1996, Circulation.
[16] J. Isner,et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.
[17] J. S. Janicki,et al. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. , 1995, Cardiovascular research.
[18] T. Kitazono,et al. Evidence that angiotensin II is present in human monocytes. , 1995, Circulation.
[19] G. Tsujimoto,et al. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leucocytes. , 1995, Endocrine journal.
[20] Y. Yamaguchi,et al. Release of endogenous ATP from the caudal artery in rats with arteriosclerosis. , 1994, European journal of pharmacology.
[21] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[22] E. H. Blaine,et al. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. , 1993, The Journal of clinical investigation.
[23] R D Kamm,et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. , 1992, Circulation research.
[24] A. Chobanian,et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1992, Hypertension.
[25] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[26] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[27] G. Åberg,et al. Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys , 1990, Journal of cardiovascular pharmacology.
[28] J. Weinstock,et al. Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni. , 1987, Cellular immunology.
[29] A. Becker,et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.